Abstract
Parkinson disease (PD) is the second most prevalent neurodegenerative disorder after Alzheimer’s disease (AD). The formation of the cytoplasmic inclusions named “Lewy bodies” in the brain, considered to be a marker for neuronal degeneration in PD and dementia with Lewy bodies. However, Lewy bodies (LBs) are also observed in approximately 60 percent of both sporadic and familial cases with AD. LBs consist of fibrils mainly formed by post-translational modified α-synuclein (α-syn) protein. The modifications can be truncation, phosphorylation, nitration and mono-, di-, or tri-ubiquitination. Development of disease seems to be linked to events that increase the concentration of α-syn or cause its chemical modification, either of which can accelerate α-syn aggregation. Examples of such events include increased copy number of genes, decreased rate of degradation via the proteasome or other proteases, or modified forms of α-syn. As the aggregation of α-syn in the brain has been strongly implicated as a critical step in the development of several neurodegenerative diseases, the current search for disease-modifying drugs is focused on modification of the process of α-syn deposition in the brain. Recently researchers have screened and designed various molecules that are selectively focused on inhibiting or preventing α-syn aggregation and toxicity. Another strategy that has emerged is to target α-syn expression as a potential therapy for neurodegenerative diseases associated with LBs.
Keywords: Alpha-synuclein, alzheimer’ s disease, drug discovery, lewy bodies, neurodegeneration, parkinson’ s disease, dementia with lewy bodies and protein aggregation.
Current Alzheimer Research
Title:The Role of α-Synuclein in Neurodegenerative Diseases: From Molecular Pathways in Disease to Therapeutic Approaches
Volume: 10 Issue: 6
Author(s): Karima M. Al-Mansoori, Mohamed Y. Hasan, Abdulmonem Al-Hayani and Omar M.A. El-Agnaf
Affiliation:
Keywords: Alpha-synuclein, alzheimer’ s disease, drug discovery, lewy bodies, neurodegeneration, parkinson’ s disease, dementia with lewy bodies and protein aggregation.
Abstract: Parkinson disease (PD) is the second most prevalent neurodegenerative disorder after Alzheimer’s disease (AD). The formation of the cytoplasmic inclusions named “Lewy bodies” in the brain, considered to be a marker for neuronal degeneration in PD and dementia with Lewy bodies. However, Lewy bodies (LBs) are also observed in approximately 60 percent of both sporadic and familial cases with AD. LBs consist of fibrils mainly formed by post-translational modified α-synuclein (α-syn) protein. The modifications can be truncation, phosphorylation, nitration and mono-, di-, or tri-ubiquitination. Development of disease seems to be linked to events that increase the concentration of α-syn or cause its chemical modification, either of which can accelerate α-syn aggregation. Examples of such events include increased copy number of genes, decreased rate of degradation via the proteasome or other proteases, or modified forms of α-syn. As the aggregation of α-syn in the brain has been strongly implicated as a critical step in the development of several neurodegenerative diseases, the current search for disease-modifying drugs is focused on modification of the process of α-syn deposition in the brain. Recently researchers have screened and designed various molecules that are selectively focused on inhibiting or preventing α-syn aggregation and toxicity. Another strategy that has emerged is to target α-syn expression as a potential therapy for neurodegenerative diseases associated with LBs.
Export Options
About this article
Cite this article as:
Al-Mansoori M. Karima, Hasan Y. Mohamed, Al-Hayani Abdulmonem and El-Agnaf M.A. Omar, The Role of α-Synuclein in Neurodegenerative Diseases: From Molecular Pathways in Disease to Therapeutic Approaches, Current Alzheimer Research 2013; 10 (6) . https://dx.doi.org/10.2174/1567205011310060002
DOI https://dx.doi.org/10.2174/1567205011310060002 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
mTOR Inhibitors in Tuberous Sclerosis Complex
Current Neuropharmacology Axonopathy Likely Initiates Neuropathological Processes Via a Mechanism of Axonal Leakage in Alzheimer's Mouse Models
Current Molecular Medicine Pharmacological Treatment of Attention Deficit Hyperactivity Disorder (ADHD): A Systematic Review of Recent Data
Current Psychopharmacology Metabotropic Glutamate Receptor Genes as Candidates for Pharmacogenetic Studies of Current and Future Antipsychotic Agents in Schizophrenia
Current Pharmacogenomics Liver Injury Associated with Antidepressants
Current Drug Safety Pharmacogenetic Variation in Drug Oxidizing CYPs: Impact on Drug Therapy, Drug Safety and Drug Interactions
Current Pharmacogenomics Subtypes of Antiphospholipid Antibodies in Neurologic Disorders: An Observational Study
Current Rheumatology Reviews Cannabinoids and Neuropathic Pain
Mini-Reviews in Medicinal Chemistry Psychopharmacology for Patients with Parkinson’s Disease and Deep Brain Stimulation: Lessons Learned in an Academic Center
Current Psychopharmacology Epigenetics in the Cerebrovascular System: Changing the Code without Altering the Sequence
Current Neurovascular Research Propitious Profile of Peppery Piperine
Current Molecular Pharmacology Possible Human Endogenous Cryogens
Current Protein & Peptide Science NLRP3 Inhibitors as Potential Therapeutic Agents for Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Design An Overview and Therapeutic Promise of Nutraceuticals Against Sports-Related Brain Injury
Current Molecular Pharmacology Patent Selections
Recent Patents on Biomedical Engineering (Discontinued) Exosomes: A Novel Therapeutic Paradigm for the Treatment of Depression
Current Drug Targets Neurovascular Mechanisms of Hypertension in Pregnancy
Current Neurovascular Research The Importance of the Adenosine A2A Receptor-Dopamine D2 Receptor Interaction in Drug Addiction
Current Medicinal Chemistry Leflunomide, a Reversible Monoamine Oxidase Inhibitor
Central Nervous System Agents in Medicinal Chemistry Docosahexaenoic Acid and Membrane Lipid Domains
Current Organic Chemistry